ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup-Reference-Cited by-同舟云学术

ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup

Published:2018-10-12 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Chan Chang S.,Laddha Saurabh V.^ORCID,Lewis Peter W.^ORCID,Koletsky Matthew S.,Robzyk Kenneth,Da Silva Edaise,Torres Paula J.,Untch Brian R.,Li Janet,Bose Promita,Chan Timothy A.^ORCID,Klimstra David S.,Allis C. David,Tang Laura H.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-06498-2.pdf

Reference41 articles.

1. Halfdanarson, T. R., Rabe, K. G., Rubin, J. & Petersen, G. M. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann. Oncol. 19, 1727–1733 (2008).

2. Tang, L. H. & Klimstra, D. S. Conundrums and caveats in neuroendocrine tumors of the pancreas. Surg. Pathol. Clin. 4, 589–624 (2011).

3. Tang, L. H., Basturk, O., Sue, J. J. & Klimstra, D. S. A practical approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the pancreas. Am. J. Surg. Pathol. 40, 1192–1202 (2016).

4. Tang, L. H. et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin. Cancer Res. 22, 1011–1017 (2016).

5. Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199–1203 (2011).

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ARX, PDX1, ISL1, and CDX2 Expression Distinguishes 5 Subgroups of Pancreatic Neuroendocrine Tumors With Correlations to Histology, Hormone Expression, and Outcome;Modern Pathology;2024-11

2. Genomic Landscape of Pancreatic Neuroendocrine Tumors and Implications for Clinical Practice;JCO Precision Oncology;2024-09

3. Proteogenomic characterization of pancreatic neuroendocrine tumors uncovers hypoxia and immune signatures in clinically aggressive subtypes;iScience;2024-08

4. Loss of ATRX and DAXX in pancreatic neuroendocrine tumors: Association with recurrence risk, cellular phenotype, and heterogeneity;Human Pathology;2024-08

5. A cross-species transcriptomic analysis reveals a novel 2-dimensional classification system explaining the invasiveness heterogeneity of pancreatic neuroendocrine tumor;Cancer Letters;2024-07